What question did this study set out to answer?

To assess the efficacy of flow cytometry-based MRD monitoring for relapse prediction in intermediate-risk AML patients.

December 8, 2025Blood

Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries

View Full Paper

Ask AI

Bookmark

Authors

This study demonstrates effective risk stratification in AML, implying advanced MRD protocols may enhance relapse prediction.

To assess the efficacy of flow cytometry-based MRD monitoring for relapse prediction in intermediate-risk AML patients.
Evaluated post-induction MRD1 and MRD2 using an 8-color MPFC panel
Categorized MRD into Positive, Low Positive, and Negative
Analyzed clinical endpoints such as relapse-free survival and cumulative incidence of relapse using Kaplan-Meier and Cox regression
MRD positivity found in 21% of patients at MRD1 and 12.5% at MRD2
Significant association between low positive MRD and poorer relapse-free survival
MRD clearance by MRD2 linked to improved outcomes

Marani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

This study demonstrates effective risk stratification in AML, implying advanced MRD protocols may enhance relapse prediction.

To assess the efficacy of flow cytometry-based MRD monitoring for relapse prediction in intermediate-risk AML patients.
Evaluated post-induction MRD1 and MRD2 using an 8-color MPFC panel
Categorized MRD into Positive, Low Positive, and Negative
Analyzed clinical endpoints such as relapse-free survival and cumulative incidence of relapse using Kaplan-Meier and Cox regression
MRD positivity found in 21% of patients at MRD1 and 12.5% at MRD2
Significant association between low positive MRD and poorer relapse-free survival
MRD clearance by MRD2 linked to improved outcomes

Marani et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark